Empowered Funds LLC Has $1.90 Million Position in Collegium Pharmaceutical, Inc. $COLL

Empowered Funds LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 75.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,384 shares of the specialty pharmaceutical company’s stock after acquiring an additional 24,734 shares during the period. Empowered Funds LLC’s holdings in Collegium Pharmaceutical were worth $1,898,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Collegium Pharmaceutical by 65.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after purchasing an additional 518,721 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Collegium Pharmaceutical in the 1st quarter worth about $463,000. Intech Investment Management LLC increased its position in Collegium Pharmaceutical by 25.5% in the 4th quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock worth $5,040,000 after purchasing an additional 22,146 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth about $686,000.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $29.11 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.90 and a fifty-two week high of $50.79. The stock’s 50-day moving average is $34.86 and its two-hundred day moving average is $37.13. The firm has a market cap of $944.04 million, a P/E ratio of 14.27 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.68 EPS. On average, analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, exceeding the $1.72 analyst consensus and rising from $1.68 a year earlier. Revenue increased 6% year over year to approximately $199.9 million, slightly above estimates. Collegium Q2 earnings beat
• Positive Sentiment: JORNAY PM revenue grew 41% to $46.1 million, while the newly acquired AZSTARYS contributed $12.9 million in partial-quarter sales. Collegium completed the AZSTARYS acquisition, adding a complementary ADHD treatment with expected patent protection through 2037. Collegium Q2 financial results
• Positive Sentiment: Operating cash flow was $71.3 million, and adjusted EBITDA rose 8% year over year to $113.8 million, supporting the company’s ability to fund operations and integrate AZSTARYS.
• Neutral Sentiment: Needham maintained a Buy rating but lowered its price target from $56 to $46, reflecting a more cautious outlook while still implying substantial potential upside from recent trading levels. Needham price target update
• Negative Sentiment: Collegium reduced 2026 product-revenue guidance to $825 million-$855 million from $865 million-$895 million and cut adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. Management attributed the reductions mainly to weaker-than-expected Nucynta authorized-generic revenue and lower net pricing.
• Negative Sentiment: The pain portfolio declined 9% to $140.9 million, including a 24% drop in Nucynta revenue and a 14% decline in Xtampza ER. GAAP results also shifted to a $15.1 million net loss from $12.0 million of profit, while operating expenses rose 45%, partly due to acquisition-related costs. Collegium Q2 2026 earnings call transcript

Analyst Ratings Changes

Several equities research analysts have recently issued reports on COLL shares. Needham & Company LLC reduced their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.